Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 15 Jul, 01:30 am
Corporate events, including significant financing rounds and strategic product launches, were the primary catalysts for the notable stock gains across these companies. The biotech sector , represented by Q32 Bio Inc. and Agenus Inc., demonstrated strong performance driven by subs
Clinical trial failures significantly impacted biotech stocks, leading to sharp declines for companies like Aardvark Therapeutics, Inc. Corporate governance issues , such as board changes and audit committee resignations, created investor uncertainty for firms including Julong Ho
Analyst firm Jefferies maintained a "Buy" rating for Biogen , signaling confidence in the biotechnology stock . The U.S. FDA approval of an at-home starting dose for LEQEMBI enhances patient convenience for Alzheimer's treatment . New clinical data confirms the effectiveness and
Bank of America (NYSE: BAC) is set to release its quarterly earnings report on July 14, 2026, amidst a busy week for the banking sector , with competitors like JPMorgan Chase & Co (NYSE: JPM) and Wells Fargo & Company (NYSE: WFC) also reporting. Analysts project a consensus earni
Wells Fargo & Company (NYSE:WFC) demonstrates stable financial performance and optimistic analyst sentiment ahead of its Q2 2026 earnings release. The broader banking sector is experiencing favorable market conditions, supported by a robust economic environment, dynamic capital m
Ball Corporation is a global leader in sustainable aluminum packaging and aerospace, showcasing diversified operations. Despite a recent minor pullback, the stock has demonstrated solid monthly performance, potentially offering a buying opportunity for investors. Analysts project
Jefferies raised its price target for Tesla (NASDAQ: TSLA) to $400.00 from $375.00 , citing strong delivery numbers. Despite the increased target, Jefferies maintained a "Hold" rating, with Tesla's stock trading at $393.64 , close to the new target. Tesla's shares saw a slight di
Alnylam Pharmaceuticals (NASDAQ: ALNY) Surges on Analyst Upgrade and Robust Pipeline Growth Analyst Confidence Soars: H.C. Wainwright significantly raised its price target for Alnylam Pharmaceuticals, indicating a substantial potential upside for the stock. Exceptional Financial
JD.com (NASDAQ: JD) is a dominant force in China's e-commerce sector , competing with major players like Alibaba and PDD Holdings. Analysts project significant upside for JD.com stock , with price targets ranging from $37.00 to $41.00 , driven by a "tech rotation" into Chinese in
Analyst firm UBS reiterated a "Buy" rating for Amgen and increased its stock price target to $420.00 . Zacks Investment Research upgraded Amgen to a "Buy" (Zacks Rank #2) due to an upward trend in earnings estimates. A federal judge blocked an attempt to limit the price of Amgen'
S&P Global Inc. demonstrates robust growth potential with strong earnings projections and a recurring subscription revenue model. The company is strategically investing in artificial intelligence (AI) integrations to enhance its Capital IQ Pro platform, driving customer demand. D
An analyst at UBS has raised the price target for Eli Lilly to $1,425.00 , indicating a potential 19.76% increase from its current stock price. Eli Lilly's significant market capitalization and high valuation are primarily driven by the success of its blockbuster GLP-1 drugs , Mo
Rick Larsen of the WA02 district executed an insider sale of Abbott Laboratories (NYSE: ABT) stock, with a transaction value between $1,001 and $15,000 , on July 8, 2026. Abbott's strategic acquisition of Exact Sciences for $23 billion in March 2026 is set to bolster its oncology
Analyst Confidence: Truist Financial has raised its price target for Vertex, suggesting a potential 16.91% upside for the stock. Strategic Expansion: Vertex is acquiring Crinetics Pharmaceuticals for approximately $10 billion , significantly expanding its presence in specialty en
Intel (NASDAQ: INTC) , a leading semiconductor company , maintains a strong market position despite recent stock volatility and broader semiconductor industry trends. Analyst firm UBS raised Intel's price target to $121.00 , citing the company's strategic investments , including
Amphenol's Strong AI Sector Performance: The company, a key supplier to Nvidia , is significantly benefiting from AI data center investments , driving substantial revenue growth in its IT Datacom division. Robust Financials and Market Outperformance: Amphenol demonstrates strong
An RBC Capital analyst set a new price target of $94 for General Motors (NYSE:GM) , indicating a potential 20.76% upside from its current stock price. Investors are keenly awaiting the upcoming earnings report, with projections indicating a significant 23% increase in earnings pe
RBC Capital maintained its "Sector Perform" rating for Mobileye Global Inc. but raised its price target to $10.00 , reflecting potential upside. Mobileye is undergoing a significant strategic shift, expanding beyond ADAS to become an infrastructure provider for emerging technolog
Headlines provided by Investing.com